Payment overview · 2025
General Payments
$381.58
18 reported records · 8 companies
Healthcare provider profile · identity verified
James R Norman, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONROEVILLE, AL · NPI 1437411576
Verified facts
What the public records show
CMS Open Payments records show James R Norman, MD received $381.58 in general payments during 2025 across 18 reported records.
GlaxoSmithKline, LLC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.28 | 25.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.72 | 16.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.07 | 14.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.64 | 12.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.75 | 11.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.84 | 10.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.87 | 5.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.41 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.58 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $97.28 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $63.72 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.07 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.07 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.75 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 204 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
204 | 34 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 196 |
| Gabapentin | Gabapentin | 709 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 133 |
| Potassium Chloride | Potassium Chloride | 568 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 552 | 149 |
| Tramadol Hcl | Tramadol Hcl | 500 | 95 |
| Lisinopril | Lisinopril | 494 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 491 | 118 |
| Eliquis | Apixaban | 445 | 62 |
| Furosemide | Furosemide | 435 | 125 |
| Prednisone | Prednisone | 336 | 217 |
| Losartan Potassium | Losartan Potassium | 334 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 328 | 77 |
| Omeprazole | Omeprazole | 309 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 84 |
| Pregabalin | Pregabalin | 289 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 286 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 271 | 70 |
| Sertraline Hcl | Sertraline Hcl | 260 | 65 |
| Trazodone Hcl | Trazodone Hcl | 249 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 241 | 53 |
| Metformin Hcl | Metformin Hcl | 229 | 70 |
| Meloxicam | Meloxicam | 222 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 69 |
| Montelukast Sodium | Montelukast Sodium | 216 | 62 |
| Carvedilol | Carvedilol | 211 | 51 |
| Buspirone Hcl | Buspirone Hcl | 206 | 50 |
| Ozempic | Semaglutide | 204 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 58 |
| Donepezil Hcl | Donepezil Hcl | 187 | 38 |
| Ondansetron Odt | Ondansetron | 184 | 79 |
| Mirtazapine | Mirtazapine | 180 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 175 | 37 |
| Metformin Hcl Er | Metformin Hcl | 169 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 36 |
| Famotidine | Famotidine | 157 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 47 |
| Amitriptyline Hcl | Amitriptyline Hcl | 152 | 36 |
| Clonazepam | Clonazepam | 152 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 145 | 42 |
| Simvastatin | Simvastatin | 145 | 37 |
| Azithromycin | Azithromycin | 143 | 114 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 49 |
| Januvia | Sitagliptin Phosphate | 137 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 120 | 27 |
| Bumetanide | Bumetanide | 117 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 88 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 102 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 31 |
| Jardiance | Empagliflozin | 99 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 21 |
| Clonidine Hcl | Clonidine Hcl | 94 | 31 |
| Divalproex Sodium | Divalproex Sodium | 94 | 14 |
| Memantine Hcl | Memantine Hcl | 93 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 22 |
| Xarelto | Rivaroxaban | 92 | 11 |
| Celecoxib | Celecoxib | 91 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 23 |
| Allopurinol | Allopurinol | 87 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 87 | 23 |
| Alprazolam | Alprazolam | 86 | 17 |
| Diazepam | Diazepam | 83 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 19 |
| Cephalexin | Cephalexin | 80 | 51 |
| Cefdinir | Cefdinir | 79 | 73 |
| Fluconazole | Fluconazole | 79 | 51 |
| Nystatin | Nystatin | 78 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 67 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 17 |
| Risperidone | Risperidone | 75 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 19 |
| Baclofen | Baclofen | 71 | 11 |
| Estradiol | Estradiol | 69 | 20 |
| Lorazepam | Lorazepam | 69 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 68 | 13 |
| Meclizine Hcl | Meclizine Hcl | 68 | 26 |
| Nifedipine Er | Nifedipine | 68 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 47 |
| Bupropion Xl | Bupropion Hcl | 65 | 14 |
| Glimepiride | Glimepiride | 64 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 63 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 18 |
| Levofloxacin | Levofloxacin | 63 | 44 |
| Spironolactone | Spironolactone | 63 | 19 |
| Ezetimibe | Ezetimibe | 62 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 22 |
| Alendronate Sodium | Alendronate Sodium | 58 | 18 |
| Levetiracetam | Levetiracetam | 58 | 17 |
| Mupirocin | Mupirocin | 55 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 15 |
| Finasteride | Finasteride | 53 | 13 |
| Glipizide | Glipizide | 53 | 16 |
| Austedo | Deutetrabenazine | 51 | suppressed |
| Naproxen | Naproxen | 51 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 27 |
| Propranolol Hcl | Propranolol Hcl | 48 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 31 |
| Nitroglycerin | Nitroglycerin | 47 | 18 |
| Topiramate | Topiramate | 46 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Methocarbamol | Methocarbamol | 43 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 13 |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | 18 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | 13 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 23 |
| Ceftriaxone | Ceftriaxone Sodium | 34 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 12 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 15 |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 13 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Scopolamine | Scopolamine | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 26 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 20 |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 18 |
| Valacyclovir | Valacyclovir Hcl | 21 | 16 |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 15 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | 13 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 11 |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Prolensa | Bromfenac Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.58 · 18 records | GlaxoSmithKline, LLC. | BREZTRI, CAPLYTA, FREESTYLE LIBRE 3, Kerendia, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error